Neurocrine Shares Rise Sharply on Analyst Rating

Shares of Neurocrine Biosciences Inc. (NBIX) climbed as high as 15 percent early Friday — the highest intraday pps since December 2007 — on news that analysts at Jefferies & Co. had initiated coverage of the San Diego-based drugmaker’s stock with a ‘Buy’ rating.

Shares of NBIX are higher on the session by 13.72% at $7.21 on heavy trading volume of 963,000 shares.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.